Top Page
Clinuvel Pharmaceuticals
(Sydney:CUV)
Clinuvel Pharmaceuticals (CUV) vs. iShares MSCI Australia ETF (EWA)
Clinuvel Pharmaceuticals Business Overview & Revenue Model
Clinuvel Pharmaceuticals Earnings Call Summary
Clinuvel Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 95.02M | 95.02M | 88.18M | 78.32M | 65.72M | 47.98M |
| Gross Profit | 73.19M | 79.14M | 80.45M | 50.59M | 46.62M | 35.20M |
| EBITDA | 47.07M | 57.20M | 51.86M | 46.37M | 35.08M | 26.57M |
| Net Income | 36.17M | 36.17M | 35.64M | 30.60M | 20.88M | 24.73M |
Balance Sheet | ||||||
| Total Assets | 271.75M | 271.75M | 231.12M | 194.52M | 144.81M | 108.57M |
| Cash, Cash Equivalents and Short-Term Investments | 224.11M | 224.11M | 183.87M | 156.81M | 121.51M | 82.69M |
| Total Debt | 528.53K | 528.53K | 879.78K | 999.87K | 1.26M | 1.30M |
| Total Liabilities | 30.94M | 30.94M | 28.11M | 29.89M | 19.25M | 9.83M |
| Stockholders Equity | 240.81M | 240.81M | 203.01M | 164.63M | 125.56M | 98.74M |
Cash Flow | ||||||
| Free Cash Flow | 40.80M | 40.80M | 31.48M | 35.88M | 39.44M | 18.41M |
| Operating Cash Flow | 41.10M | 41.10M | 37.05M | 36.91M | 39.87M | 19.26M |
| Investing Cash Flow | -47.72M | -47.72M | -29.03M | -1.03M | -434.44K | -854.33K |
| Financing Cash Flow | -2.94M | -2.94M | -3.57M | -2.24M | -1.50M | -1.48M |
Clinuvel Pharmaceuticals Technical Analysis
Clinuvel Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $572.79M | 15.66 | 15.90% | 0.44% | 7.76% | 1.55% | |
| ― | $419.50M | ― | -35.86% | ― | ― | -19.21% | |
| ― | AU$1.82B | ― | -54.37% | ― | ― | -29.93% | |
| ― | AU$285.75M | -3.10 | -90.93% | ― | 456.50% | -457.14% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$699.91M | ― | -40.23% | ― | ― | -5.70% | |
| ― | AU$738.77M | ― | ― | ― | -80.08% | 59.91% |
Clinuvel Pharmaceuticals Corporate Events
In a departure from traditional presentations, Clinuvel Pharmaceuticals’ Managing Director emphasized the importance of time and cash reserves in sustaining the company’s operations and competitive advantage. The company is committed to reinvesting its cash into its proprietary technology, which it believes holds more value than external opportunities. This strategy provides Clinuvel with a four-year operational runway, credibility with partners, and the ability to absorb shocks and learn from failures, ultimately enhancing its risk management and potential for long-term success.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$32.84 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals’ recent AGM highlighted the company’s strategic focus on disciplined capital allocation and internal development. The approval of SCENESSE® by the European Medicines Agency, after initial rejections, underscores the company’s commitment to its data and team, resulting in an expanded revenue stream in Europe. Additionally, Clinuvel’s decision to invest in its own R&D, despite external skepticism, has led to breakthroughs in liquid injectable formulations, securing foundational IP. The company’s financial strategy prioritizes reinvestment in its pipeline over dividends, maintaining profitability without diluting shareholder value. This approach has enabled Clinuvel to achieve sustained growth and profitability, while exploring low-risk acquisition opportunities in North America.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$32.84 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
CLINUVEL Pharmaceuticals announced that Health Canada has requested additional time and information to complete its review of SCENESSE® for treating erythropoietic protoporphyria (EPP), extending the review into 2026. Despite the delay, Canadian patients continue to receive treatment under the Special Access Program, and the company remains committed to addressing Health Canada’s requests. This development highlights the challenges in gaining regulatory approval in new markets, potentially impacting Canadian patients’ access to the treatment.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$32.84 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
CLINUVEL PHARMACEUTICALS LIMITED has issued 77,110 fully paid ordinary shares at no issue price, as announced in compliance with the Corporations Act 2001. This strategic move is part of the company’s ongoing efforts to strengthen its market position and ensure compliance with regulatory requirements, potentially impacting its operational capabilities and stakeholder interests.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals Limited announced the cessation of 36,323 performance rights due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth prospects.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals Limited has announced the issuance of 18,483 ordinary fully paid shares to consultants as compensation for services rendered. This move is part of the company’s strategy to align consultant interests with its operational goals, potentially enhancing its market position and stakeholder engagement.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals Limited has announced the quotation of 58,627 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from October 1, 2025. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially impacting stakeholders by increasing the liquidity of its shares.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
CLINUVEL Pharmaceuticals announced that Dr. Philippe Wolgen has resumed his role as CEO, while Lachlan Hay has taken on increased responsibilities as Chief Operations Officer. This management update is part of a strategic shift to focus on specific projects, including a planned Nasdaq uplisting and clinical plans in vitiligo. The company’s recent achievements, such as the full recruitment of the CUV105 study and a European label extension, highlight its ongoing progress and potential impact on its market positioning.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
CLINUVEL has announced the advancement of new sustained-release liquid drug formulations in a preclinical program, aiming to optimize drug release kinetics and patient exposure to active ingredients. This development, stemming from a decade of research, focuses on extending the duration of peptide drugs in the bloodstream, with initial emphasis on melanocortins. The preclinical program is expected to conclude in the second half of 2026, potentially offering a flexible dosing platform for various peptides, which could enhance the company’s industry positioning and provide new options for drug delivery.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals presented new case studies at the European Academy of Dermatology and Venereology conference, demonstrating the efficacy of SCENESSE® in treating vitiligo. The studies showed significant and stable repigmentation in patients, with no unexpected safety concerns, marking a potential breakthrough for those with extensive vitiligo and offering hope for effective long-term treatment.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
CLINUVEL PHARMACEUTICALS LIMITED has announced its 2025 Annual General Meeting (AGM) to be held on October 17, 2025, in Melbourne. The meeting will address the adoption of the 2025 Remuneration Report and the re-election of two Non-Executive Directors. The company has faced strikes on its 2023 and 2024 Remuneration Reports, leading to increased transparency and adjustments in executive remuneration practices. CLINUVEL benchmarks its executive pay against a global peer group to ensure competitive packages, essential for attracting and retaining talent. This strategic approach aims to align executive incentives with company performance and shareholder interests.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$11.50 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals has reported a strong financial performance for FY2025, with A$105 million in revenues and A$35.6 million in net profit after tax, marking its eighth consecutive dividend. The company has maintained a robust balance sheet with A$224 million in cash reserves and zero debt, allowing it to self-fund operations and avoid dilutive capital raises. Clinuvel’s strategic focus on mitigating risks associated with regulatory, financial, and growth dependencies has positioned it uniquely within the biotechnology sector. The company is actively working on expanding its clinical pipeline and increasing its visibility among U.S. investors through a planned Level II ADR listing on NASDAQ, aiming to reflect its true market value.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$11.50 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
CLINUVEL PHARMACEUTICALS LTD has announced that its Annual General Meeting (AGM) will be held on October 17, 2025, with the Notice of Meeting to be lodged by September 15, 2025. This announcement is part of the company’s compliance with ASX Listing Rule 3.13.1, which also sets September 5, 2025, as the closing date for director nominations. The AGM is a significant event for shareholders, providing an opportunity to engage with the company’s strategic direction and governance.
The most recent analyst rating on (AU:CUV) stock is a Hold with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
The recent earnings call for Clinuvel Pharmaceuticals Limited painted a picture of robust growth and strategic advancements, tempered by some operational challenges. The company celebrated strong revenue growth and a solid financial position, while also acknowledging increased expenses and a regulatory setback. Clinuvel’s expansion in the U.S. and consistent profitability were highlighted as significant achievements, though delays in revenue recognition and rising operational costs posed challenges.
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of treatments for severe skin disorders, focusing on melanocortin-based therapies. The company is known for its innovative approach to addressing unmet medical needs in dermatology.
CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar to discuss its financial results for the year ending June 30, 2025. The company continues to focus on its innovative treatments, with SCENESSE® being a key product in its portfolio. The announcement highlights CLINUVEL’s ongoing commitment to addressing unmet medical needs in specialized patient populations, which may strengthen its position in the pharmaceutical industry and potentially impact stakeholders positively.
The most recent analyst rating on (AU:CUV) stock is a Hold with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals has announced its strategic plan towards diversification for the financial year ending June 2025. The company is addressing various risks and challenges, including supply chain disruptions, competition, regulatory scrutiny, and potential delays in manufacturing, which could impact its operations and market positioning. The announcement highlights the company’s proactive approach to managing uncertainties and maintaining its competitive edge in the biopharmaceutical industry.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals Limited has announced a dividend distribution of AUD 0.05 per share for its ordinary fully paid securities, with the ex-date set for September 4, 2025, and the payment date on September 19, 2025. This announcement reflects the company’s financial health and commitment to delivering value to its shareholders, potentially enhancing its position in the pharmaceutical industry by demonstrating consistent financial performance.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals reported its ninth consecutive year of revenue growth and profit, with a 10% increase in revenues to $105.3 million for the fiscal year ending June 30, 2025. The company’s net profit before tax rose by 2% to $51.6 million, driven by robust demand for SCENESSE® and higher interest income. Despite a 20% rise in expenses due to increased personnel and clinical development costs, Clinuvel maintained a strong financial position with a 22% increase in cash reserves to $224.1 million. This financial strength enables the company to self-finance its diversification plans and manage risks in a volatile macroeconomic environment.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals Ltd reported an 8% increase in revenues to A$95,017,570 and a 2% rise in net profit to A$36,172,518 for the fiscal year ending June 30, 2025. The company declared a fully franked final dividend of $0.05 per share, reflecting its steady financial performance and commitment to returning value to shareholders. This financial growth underscores Clinuvel’s strong market positioning and its ability to sustain profitability in the competitive pharmaceutical sector.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
CLINUVEL PHARMACEUTICALS announced plans to upgrade its American Depository Receipt (ADR) program to Level II and list on Nasdaq by the end of 2025, aiming to enhance U.S. visibility and investor engagement. This strategic move aligns with the company’s growing U.S. operations and increasing interest from North American investors, with 28% of its shares already held by U.S.-based investors, and is expected to broaden its market presence without raising additional capital.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals has released a statement addressing the challenges and risks associated with the development and commercialization of its pharmaceutical and PhotoCosmetic products. The company highlights potential impacts on its operations due to factors such as supply chain disruptions, regulatory scrutiny, and market competition. These challenges could affect the company’s ability to launch and supply its products, impacting stakeholders and market positioning.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$39.70 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
Clinuvel Pharmaceuticals has released a statement highlighting the potential risks and challenges it faces in developing and commercializing its products, including SCENESSE® and other PhotoCosmetic offerings. The company acknowledges the impact of global events, regulatory scrutiny, and competition on its operations, emphasizing the importance of innovative R&D and effective patent protection to maintain its industry position.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$39.70 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.